Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV

This is the authors' abstract. We don't add key points for this paper.

Women living with HIV and breast cancer have poorer survival than HIV-negative women. Efavirenz–estrogen interactions are documented; however, the survival impact is unknown. Survival between women with estrogen-receptor positive breast cancer taking efavirenz ( n = 38) and nonefavirenz regimens ( n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0–72.2 and 51.1% (95% CI 34.0–76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.